SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
XRTX
XORTX Therapeutics Inc
-24.19%
$0.62 - $0.47
Feb 7th 2023 - Mar 21st 2023
positive
negative
Dec, 11, 2022
$BIVI Biovie Pharmaceuticals $BIVI passes Zacks Equity Research's strict "Recent Price Strength screen", and comes out with glowing colors--and a prediction of further momentum for the stock in near term.
positive
negative
No reviews available.
positive
negative
Jan, 20, 2023
$XRTX Dr Allen Davidoff, the XORTX Therapeutics CEO, stated: “We are pleased to have achieved this important milestone in the development of XORLOTM, the Company’s proprietary oral formulation of oxypurinol.